We fully support the Oncidium foundation.  Great cause and great people!

The Oncidium foundation is a non-profit organization dedicated to advancing radioligand therapies for cancer care worldwide.

A non-profit organization dedicated to advancing radioligand therapies for cancer care worldwide, ensuring healthcare equity for everyone, regardless of origin or financial situation.

The generosity of donors allows the Oncidium foundation to finance the research and development of new radiotheranostics cancer treatments as well as to support cancer patients. We know that this path is not easy. We know the importance of finding the right doctor, understand the diagnosis and learn about treatment options. It is our mission to educate, raise awareness, and support cancer patients and their loved ones on this daily battle.

By supporting the Oncidium foundation projects, you put your action at the heart of the fight against cancer!

The Oncidium foundation 

Cancer Awareness

Humans

Research

Education

Health

1258415673

1435915265

1737023302

We are a nonprofit, so instead of charging fees we rely on the generosity of donors like you.

Choose a donation for Every.org

2074652487

240751341

2516130445

2624895975

2883383521

339774024

3420325072

3605944885

3755280456

3794356679

3868271524

3884515653

410756082

761293274

772217036

2729980760

3440869557

671754822

1014384873

1112422858

153399038

2028390811

220342792

2266630408

2456389719

2519810400

2539558839

2826465835

2843798242

2898624300

2916352438

3259439560

3642494300

3902459442

4054861980

4136002033

4177183036

4250940449

585491400

641510716

91682487

Help us achieve our **OBJECTIVE 365 LIVES** by supporting 365 cancer patients over the next 5 years, representing a total of 10 million euros! 
**Through collaborative efforts, we can achieve this mission.**

The RLT*-Connect Platform is an online tool that enables global donations of radiopharmaceutical-based cancer treatments, and thus, broaden the access to essential therapy for patients facing financial barriers. Radioisotope suppliers, local radiopharmacies and nuclear medicine services are already on board. Are you?

****Radioligand therapy (RLT)** is a targeted medical treatment that uses radioactive molecules to selectively deliver radiation directly to cancer cells. More and more RLTs are under development, and their adoption is steadily increasing as ongoing research continues to demonstrate their potential benefits in improving patient outcomes.*

This Fund allows U.S. donors an income **tax deduction (501(c)(3))** for their contributions, to the extent permitted by U.S. tax law. Any questions related to tax deduction please contact us: [contact@oncidium-life.org](mailto:contact@oncidium-life.org)

**THE ONCIDIUM FOUNDATION**
The Oncidium foundation is a non-profit, public benefit organization that aims to support and accelerate the development of radiotheranostics for cancer care, worldwide. For more information, visit the Oncidium foundation website:  [OncidiumFoundation.org](https://www.oncidiumfoundation.org/)

Enable Radioligand Therapy Access Worldwide.

**Enhancing access to radiotheranostics for U.S. cancer patients** in supporting them and their families throughout their treatment journey, including logistics and accommodation.

This Fund allows U.S. donors an income **tax deduction (501(c)(3))** for their contributions, to the extent permitted by U.S. tax law. Any questions related to tax deduction please contact us: [contact@oncidium-life.org](mailto:contact@oncidium-life.org)

Recent research and developments have shown the promising outcomes regarding the use of radiotheranostics in the cancer care landscape, with some approved products*   already on the market and others in early-stage development or clinical trials. However, **availability of these treatments, education and awareness of the potential use of such therapies is still very limited.**
*(* In the US, 177-Lutetium vipivotide tetraxetan was approved on March 2022, by the Food and Drug Administration for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)).*

Considering these opportunities and challenges, it is in this context that the Oncidium foundation, together with Cary's wife and daughters, have decided to open the "Cary M. Adams Fund", in honor of their late husband and father, Mr. Cary M. Adams, a firm believer in the potential of radiotheranostics-based treatments for cancer care, to support cancer patients access to radiotheranostics in the US.

**CARY M. ADAMS** September 5, 1948 - September 9, 2022
Cary was an attorney & investor with an entrepreneurial spirit, a passion for innovation, and an unquenchable thirst for knowledge. Despite his many professional pursuits, Cary's family and community always came first. In Cary's final years, he became both an advocate for & participant in research of radiotheranostic cancer treatments.

**THE ONCIDIUM FOUNDATION**
The Oncidium foundation is a non-profit, public benefit organization that aims to support and accelerate the development of radiotheranostics for cancer care, worldwide. For more information, visit the Oncidium foundation website:  [OncidiumFoundation.org](https://www.oncidiumfoundation.org/)

Improving access to radiotheranostics for US cancer patients

The Oncidium foundation

Fundraisers

Donors

.css-1d3w5wq{width:100%;}.css-yi15dt{display:inline-block;--textSize:2rem;--lineHeight:2.4rem;line-height:var(--lineHeight);font-size:var(--textSize);width:100%;}The Oncidium foundation

Fundraisers

Donors

The Oncidium foundation